Chaozhou Three-Circle(Group)(06951): Partial exercise of over-allotment option, price stabilization actions, and end of price stabilization period.
Sanhua Group (06951) announced that the exclusive overall coordinator (acting on its own and on behalf of international underwriters) has partially exercised the over-allotment option stated in the prospectus on August 5, 2026, involving a total of 8.8569 million H shares, equivalent to approximately 12.41% of the total number of shares available for subscription under the global offering (before any exercise of the over-allotment option). The over-allotted shares will be issued by the company at a price of HKD 100.30 per H share. The over-allotted shares will be used to facilitate the delivery of part of the H shares to those investors who have agreed to delay the delivery of the relevant shares subscribed under the global offering. In addition, the stabilization period for the global offering ended on August 5, 2026.
Chaozhou Three-Circle (Group) (06951) announced that the sole overall coordinator (acting on its own behalf and representing international underwriters) has partially exercised the over-allotment option described in the prospectus on August 5, 2026, involving a total of 8.8569 million H shares, accounting for approximately 12.41% of the total shares available for subscription in the global offering (before any over-allotment option is exercised). The over-allotted shares will be issued by the company at a price of HKD 100.30 per H share. The over-allotted shares will be used to facilitate the delivery of a portion of the H shares to the subscribers who have agreed to delay the delivery of the relevant shares they subscribed for in the global offering. In addition, the stabilization period for the global offering ended on August 5, 2026.
Related Articles
CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.
US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.
LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.
CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.
US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.
LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.
RECOMMEND
